Immediate and delayed hyperbaric oxygen therapy as a neuroprotective treatment for traumatic brain injury in mice

Baratz-Goldstein, Renana; Toussia-Cohen, Shlomi; Elpaz, Aviya; Rubovitch, Vardit; Pick, Chaim G.

doi:10.1016/j.mcn.2017.06.004

Cited by 37 publications

(27 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“… 171 The treatment with hyperbaric oxygen (HBO) alleviates the inflammatory response in experimental TBI via modulating microglial NLRP3 inflammasome signaling and reducing IL-1β/IL-18 accumulation. 172 , 173 NLRP3 inhibitors such as BAY 11-7082 (via NFκB) or A438079 (via P2X7) have been shown to inhibit the inflammatory response and improve functional recovery after TBI. 75 , 174 Mangiferin has been extensively used as an anti-inflammatory drug and its neuroprotective effect after CNS injury is also attributed to NLRP3 inhibition.…”

Section: Immunotherapy At the Innate Immune Response After Cns Injurymentioning

confidence: 99%

Potential immunotherapies for traumatic brain and spinal cord injury

Putatunda

Bethea

2018

Chinese Journal of Traumatology

View full text Add to dashboard Cite

Traumatic injury of the central nervous system (CNS) including brain and spinal cord remains a leading cause of morbidity and disability in the world. Delineating the mechanisms underlying the secondary and persistent injury versus the primary and transient injury has been drawing extensive attention for study during the past few decades. The sterile neuroinflammation during the secondary phase of injury has been frequently identified substrate underlying CNS injury, but as of now, no conclusive studies have determined whether this is a beneficial or detrimental role in the context of repair. Recent pioneering studies have demonstrated the key roles for the innate and adaptive immune responses in regulating sterile neuroinflammation and CNS repair. Some promising immunotherapeutic strategies have been recently developed for the treatment of CNS injury. This review updates the recent progress on elucidating the roles of the innate and adaptive immune responses in the context of CNS injury, the development and characterization of potential immunotherapeutics, as well as outstanding questions in this field.

show abstract

Section: Immunotherapy At the Innate Immune Response After Cns Injurymentioning

confidence: 99%

Potential immunotherapies for traumatic brain and spinal cord injury

Putatunda

Bethea

2018

Chinese Journal of Traumatology

View full text Add to dashboard Cite

show abstract

Section: Traumatic Brain Injuries‐induced Ad Animal Modelmentioning

confidence: 99%

“…TBI-induced AD models have been developed to mimic the sAD pathological changes in the brain. Controlled cortical impact (CCI) model,[102][103][104] fluid percussion injury (FPI) model,[105][106][107][108] weight drop model,103,[109][110][111] and blast injury (BI) model[112][113][114][115] can be used to induce TBI in animals. According to the severity of the injury, mild, moderate, and severe TBI can be selected.…”

mentioning

confidence: 99%

“…According to the severity of the injury, mild, moderate, and severe TBI can be selected. In general, the elevated level of phosphorylated Tau, the expression of Aβ, degradation of white matter, BBB dysfunction as well as neurogenic inflammation in hippocampus were observed in TBI models [101][102][103][104][105][106][107][108][109][110][111][112][113][114][115][116][117][118]. Wang et al discovered that TBI induced the activation of the calpain-2-PTPN13-c-Abl pathway contributed to promoted abnormal Tau aggregation and NFTs formation.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Advance of sporadic Alzheimer's disease animal models

Zhang

Chen

Mak

et al. 2019

Medicinal Research Reviews

View full text Add to dashboard Cite

Alzheimer's disease (AD), the most common form of dementia, is a progressive neurodegenerative disease. In the past decades, numbers of promising drug candidates showed significant anti‐AD effects in preclinical studies but failed in clinical trials. One of the major reasons might be the limitation of appropriate animal models for evaluating anti‐AD drugs. More than 95% of AD cases are sporadic AD (sAD). However, the anti‐AD drug candidates were mainly tested in the familial AD (fAD) animal models. The diversity between the sAD and fAD might lead to a high failure rate during the development of anti‐AD drugs. Therefore, an ideal sAD animal model is urgently needed for the development of anti‐AD drugs. Here, we summarized the available sAD animal models, including their methodology, pathologic features, and potential underlying mechanisms. The limitations of these sAD animal models and future trends in the field were also discussed.

show abstract

“…In animal models, several studies have investigated HBOT's influence on myelin basic protein (Mbp) and remyelination. Baratz-Goldstein et al [68] studied these effects in a mouse model of mild TBI, applying either immediate or delayed HBOT treatment. They found that both treatments ameliorated the reduced Mbp expression and demyelination compared to the untreated control group, and that both the treated groups and the sham group had the same measured amount of Mbp expression [68].…”

Section: The Impact Of Hbot On Alterations In White Mattermentioning

confidence: 99%

Molecular and Therapeutic Aspects of Hyperbaric Oxygen Therapy in Neurological Conditions

Fischer

Barak

2020

Biomolecules

View full text Add to dashboard Cite

In hyperbaric oxygen therapy (HBOT), the subject is placed in a chamber containing 100% oxygen gas at a pressure of more than one atmosphere absolute. This treatment is used to hasten tissue recovery and improve its physiological aspects, by providing an increased supply of oxygen to the damaged tissue. In this review, we discuss the consequences of hypoxia, as well as the molecular and physiological processes that occur in subjects exposed to HBOT. We discuss the efficacy of HBOT in treating neurological conditions and neurodevelopmental disorders in both humans and animal models. We summarize by discussing the challenges in this field, and explore future directions that will allow the scientific community to better understand the molecular aspects and applications of HBOT for a wide variety of neurological conditions.

show abstract

Immediate and delayed hyperbaric oxygen therapy as a neuroprotective treatment for traumatic brain injury in mice

Cited by 37 publications

References 50 publications

Potential immunotherapies for traumatic brain and spinal cord injury

Potential immunotherapies for traumatic brain and spinal cord injury

Advance of sporadic Alzheimer's disease animal models

Molecular and Therapeutic Aspects of Hyperbaric Oxygen Therapy in Neurological Conditions

Contact Info

Product

Resources

About